Article: Pfizer drops development of 2 late-stage drugs

Pfizer Inc. said Tuesday it is ending development of two medicines that had been in final human testing in order to shift funding and staff to other experimental drugs with more potential.

The world's biggest drugmaker said it decided to halt further testing of compounds to treat fibromyalgia and generalized anxiety disorder after reviewing its existing and experimental primary-care drugs.

"They're not products that really meet an unmet medical need," spokeswoman Kristen Neese told The Associated Press. "We'd rather devote our resources to other areas."

Neither compound had been seen as a likely blockbuster because other drugs to treat those ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!